A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B

Journal of Clinical Virology

Volumn 51, Issue 3, 2011, Pages 175-178

  Sonneveld, Milan J ^a   Rijckborst, Vincent ^a   Boucher, Charles A B ^a   Zwang, Louwerens ^a   Beersma, Matthias F C ^a   Hansen, Bettina E ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Architect; Elecsys; HBV genotype; Hepatitis B surface Antigen; Prediction of response

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B;

ARCHITECT ASSAY; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; ELECSYS ASSAY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; THAWING; VIRUS GENE;

DRUG MONITORING; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LAMIVUDINE; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79959247715     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.04.005     Document Type: Article

References (22)

1. Dienstag J.L. Hepatitis B virus infection. N Engl J Med 2008, 359:1486-1500.
2. Wursthorn K., Lutgehetmann M., Dandri M., Volz T., Buggisch P., Zollner B., et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006, 44:675-684.
3. Thompson A.J., Nguyen T., Iser D., Ayres A., Jackson K., Littlejohn M., et al. Serum Hepatitis B surface Antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010, 51:1933-1944.
4. Fattovich G., Olivari N., Pasino M., D'Onofrio M., Martone E., Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008, 57:84-90.
5. Brunetto M.R., Oliveri F., Colombatto P., Moriconi F., Ciccorossi P., Coco B., et al. Use of Hepatitis B surface Antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010, 139(2):483-490.
6. Nguyen T., Thompson A.J., Bowden S., Croagh C., Bell S., Desmond P.V., et al. Hepatitis B surface Antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010, 52:508-513.
7. Jaroszewicz J., Serrano B.C., Wursthorn K., Deterding K., Schlue J., Raupach R., et al. Hepatitis B surface Antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010, 52:514-522.
8. Lau G., Marcellin P., Brunetto M., Piratvisuth T., Kapprell H.-P., Messinger D., et al. On-treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2 in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2009, 50:S333.
9. Tangkijvanich P, Komolmit P, Mahachai V, Sa-Nguanmoo P, Theamboonlers A, Poovorawan Y. Comparison between quantitative Hepatitis B surface Antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol Res.
10. Sonneveld M.J., Rijckborst V., Boucher C.A., Hansen B.E., Janssen H.L. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment Hepatitis B surface Antigen decline. Hepatology 2010, 52:1251-1257.
11. Brunetto M.R., Moriconi F., Bonino F., Lau G.K., Farci P., Yurdaydin C., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49:1141-1150.
12. Moucari R., Mackiewicz V., Lada O., Ripault M.P., Castelnau C., Martinot-Peignoux M., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49:1151-1157.
13. Deguchi M., Yamashita N., Kagita M., Asari S., Iwatani Y., Tsuchida T., et al. Quantitation of Hepatitis B surface Antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004, 115:217-222.
14. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005, 365:123-129.
15. Hussain M., Chu C.J., Sablon E., Lok A.S. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol 2003, 41:3699-3705.
16. Muhlbacher A., Weber B., Burgisser P., Eiras A., Cabrera J., Louisirirotchanakul S., et al. Multicenter study of a new fully automated HBsAg screening assay with enhanced sensitivity for the detection of HBV mutants. Med Microbiol Immunol 2008, 197:55-64.
17. Chan H.L., Wong V.W., Tse A.M., Tse C.H., Chim A.M., Chan H.Y., et al. Serum Hepatitis B surface Antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007, 5:1462-1468.
18. Heathcote E.J., Marcellin P., Buti M., Gane E., De Man R.A., Krastev Z., et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011.
19. Rijckborst V., Ter Borg M.J., Cakaloglu Y., Ferenci P., Tabak F., Akdogan M., et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010, 105:1762-1769.
20. Rijckborst V., Hansen B.E., Cakaloglu Y., Ferenci P., Tabak F., Akdogan M., et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010, 52:454-461.
21. Manesis E.K., Hadziyannis E.S., Angelopoulou O.P., Hadziyannis S.J. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007, 12:73-82.
22. Zoutendijk R., Hansen B., van Vuuren A.J., Boucher C.A., Janssen H.L. Prediction of HBsAg loss using HBsAg decline after long-term virological response to nucleo(s)tide analogue therapy for chronic hepatitis B. Hepatology 2010, 52:381.